New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 5, 2012
06:14 EDTHES, AAPL, RDS.A, PTROn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Russia is close to joining the WTO, a landmark move to integrate their economy into the international trading system, but U.S. firms may be left out because of restrictions on trade, the Wall Street Journal reports...Talks to resolve U.S. and European price fixing probes into e-books are picking up as three international publishers may want to settle, while Apple (AAPL) and others resist, sources say, the Wall Street Journal reports...REUTERS: PetroChina (PTR) is in talks with Royal Dutch Shell (RDS.A) and Hess (HES) to explore shale oil in Santanghu Basin in China's northwestern Xinjiang region, Reuters reports...BLOOMBERG: Four Federal Reserve regional bank presidents who vote on monetary policy this year see less of a need for the Fed to spur the economy with new accommodation, Bloomberg reports...For the first time in 2012, gold traders are bearish after the Fed signaled it may refrain from more monetary stimulus and jewelers in India, the biggest bullion market, closed to protest a new tax, Bloomberg reports.
News For A;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
07:26 EDTHESUBS to hold a conference
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
10:01 EDTHESOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:44 EDTHESHess Corp. downgraded to Neutral from Buy at Goldman
Goldman downgraded Hess to Neutral and lowered its price target to $68 from $80 based on reduced upside from lower oil/gas price forecasts.
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
May 13, 2015
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use